Arkolith/Insider Trading/ADAP/Form 4

Rawcliffe Adrian

Chief Executive Officer, DirectorAdaptimmune Therapeutics PLC (ADAP) · full profile →Form 4 · filed Jan 17, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$28K
Net Open-Market Flow
-$28K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 17, 2024Sell(S)30K$0.67$20K45K
Jan 16, 2024Sell(S)9K$0.79$7K14K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-004564) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML